How to Minimize API Loss: A Case Study in Aseptic Fill/Finish
With API (active pharmaceutical ingredient) values continuing to climb as production scales conversely drop, it is time to rethink our aseptic filling processes to minimize
Category: Drug Product Manufacturing
The Make Versus Buy Dilemma: Evaluating your Aseptic Fill/Finish Manufacturing Strategy
Every biopharma company is eventually faced with the “make versus buy” decision – should they do the fill/finish manufacturing of their drug product in-house or
New manufacturing strategies for the precision medicine future
Blockbuster drugs and one-size-fits-all treatments now share portfolio space with highly targeted therapies for smaller patient populations. This new era is an opportunity for savvy
Our top picks for BIO International 2019
The BIO International 2019 conference is only one week away! Here at Argonaut, our team is preparing for a week filled with partnership meetings and
Selecting the Right CDMO Partner – Three Keys to Success
Outsourcing pharmaceutical manufacturing is becoming essential to remain competitive in the industry. The rise of small-batch personalized medicines and “virtual companies” are key drivers to retain flexible,
Facility of the Future: Our takeaways from the ISPE Aseptic Conference 2019
ISPE Aseptice Conference – “Facility of the Future” The always-essential 2019 ISPE Aseptic Conference was held in North Bethesda, MD and we were there to